Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study / Passamonti F.; Palandri F.; Saydam G.; Callum J.; Devos T.; Guglielmelli P.; Vannucchi A.M.; Zor E.; Zuurman M.; Gilotti G.; Zhang Y.; Griesshammer M.. - In: THE LANCET. HAEMATOLOGY. - ISSN 2352-3026. - ELETTRONICO. - 9:(2022), pp. e480-e492. [10.1016/S2352-3026(22)00102-8]
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Guglielmelli P.Writing – Original Draft Preparation
;Vannucchi A. M.Writing – Original Draft Preparation
;
2022
Abstract
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Passamonti_Lancet Haematology 2022.pdf
Accesso chiuso
Licenza:
Tutti i diritti riservati
Dimensione
616.37 kB
Formato
Adobe PDF
|
616.37 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
